PYXS Pyxis Oncology Inc
2,475
$4.35
$0.01
(0.23%)
| Watchers | 2,475 |
| 52-Wk Low | $1.35 |
| 52-Wk High | $6.85 |
| Market Cap | $255.52M |
| Volume | 118,929.00 |
| 52-Wk High | $6.85 |
| 52-Wk Low | $1.35 |
Pyxis Oncology (NASDAQ:PYXS) vs. NewAmsterdam Pharma (NASDAQ:NAMS) Financial SurveyTicker Report • about 1 month ago
Pyxis Oncology (NASDAQ:PYXS - Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the...
Share to Feed
For the last three days, A.I.dvisor has detected that PYXS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
For the last three days, A.I.dvisor has detected that PYXS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...
For the last three days, A.I.dvisor has detected that PYXS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's...
Pyxis Oncology files to sell 10.46M common shares for holders...
For the last three days, A.I.dvisor has detected that PYXS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
This is a signal that PYXS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...